Breaking Barriers: Japan's PMDA To Open First Global Office, In D.C.

Plus Bangkok Training Hub

Through a new full-time office in the US capital, Japan's drug regulator aims to provide essential regulatory information to help US bioventures enter the Japanese market at an early stage.

The first foreign PMDA office in Washington D.C. will offer free consultation on entering the Japanese market.
PMDA's first full-time foreign office will offer free consultations on entering Japanese market • Source: Shutterstock

To attract more new drugs still at the early stages of development at bioventures to Japan, the country has kick-started an official plan to open the first full-time foreign office of its Pharmaceuticals and Medical Devices Agency (PMDA), in Washington D.C.

More from Japan

Japan Expands Priority R&D List For Regular Vaccinations

 
• By 

Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.

Japan Recommends Beyonttra, Raises Enhertu Price

 
• By 

Japan recommends eight new drugs for approval, including two for cardiomyopathy, and will also raise prices for multiple products, including Enhertu, on 1 April.

Japan PM Delays Revision Of High-Cost Healthcare Benefit After Patient Protests

 
• By 

A plan to reduce benefits under Japan's financial safety net for patients contributing to the costs of their long-term medical care is being reconsidered by the government following protests from patient and doctor groups.

Opposition Tempers Cuts To Japan’s High-Cost Healthcare Benefits

 
• By 

Japan's MHLW has decided to tone down planned policy revisions that would have cut benefits under a patient support scheme for high-priced drugs, after resistance from patient groups.

More from Asia

China Signals Commercial Insurance, Biotech And Foreign-Owned Hospitals As Policy Priorities

 
• By 

The main 2025 policy priorities for China's government as outlined in an annual report will include the strengthening of commercial insurance for innovative drugs and opening up cell and gene therapy and the hospital sector to foreign investment.

Japan Recommends Beyonttra, Raises Enhertu Price

 
• By 

Japan recommends eight new drugs for approval, including two for cardiomyopathy, and will also raise prices for multiple products, including Enhertu, on 1 April.

Japan PM Delays Revision Of High-Cost Healthcare Benefit After Patient Protests

 
• By 

A plan to reduce benefits under Japan's financial safety net for patients contributing to the costs of their long-term medical care is being reconsidered by the government following protests from patient and doctor groups.